Pancreatic Cancer Research

ResearcherAarhus University HospitalActive in the last 2 years

Britta Weber

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7099-1204; OpenAlex author ID A5023373846. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: 1 paper

Papers 9

  1. ABCG2 protein expression in tumors of patients with non-resectable pancreatic cancer treated with gemcitabine and nab-paclitaxel. Co-author DOI 10.3389/fonc.2025.1558184↗
  2. Adaptive MRI-guided stereotactic body radiation therapy for locally advanced pancreatic cancer - A phase II study. Co-author DOI 10.1016/j.radonc.2024.110347↗
  3. A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic c… Co-author DOI 10.1186/s12885-023-11035-6↗
  4. A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic c… Co-author DOI 10.21203/rs.3.rs-2955930/v1↗
  5. Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma-A Critical Review of Randomised Trials. Co-author DOI 10.3390/curroncol30070499↗
  6. Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer. Co-author DOI 10.1080/0284186x.2021.2012252↗
  7. Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age: A Nationwide Real-World Danish Registry Study. Co-author DOI 10.1097/mpa.0000000000001833↗
  8. Pilot Study Experiences With Hyperpolarized [1-13 C]pyruvate MRI in Pancreatic Cancer Patients. Last author DOI 10.1002/jmri.26888↗
  9. Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study. Co-author DOI 10.1016/j.ejca.2020.01.015↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Per Pfeiffer · 7 shared papers, 2020–2024 · strength 1.07
  2. Morten Bækbo Ladekarl · 7 shared papers, 2020–2025 · strength 1.04
  3. Louise S. Rasmussen · 5 shared papers, 2020–2023 · strength 0.67
  4. Sönke Detlefsen · 4 shared papers, 2020–2024 · strength 0.61
  5. Michael Bau Mortensen · 3 shared papers, 2020–2024 · strength 0.49
  6. Inna Markovna Chen · 3 shared papers, 2022–2023 · strength 0.46
  7. Susy Shim · 2 shared papers, 2023–2025 · strength 0.43
  8. Mathilde Weisz Ejlsmark · 2 shared papers, 2023–2024 · strength 0.41
  9. Uffe Bernchou Jensen · 2 shared papers, 2023–2024 · strength 0.41
  10. Claus Wilki Fristrup · 3 shared papers, 2020–2022 · strength 0.34
  11. Gabor Istvan Liposits · 2 shared papers, 2023 · strength 0.32
  12. Stine Brændegaard Winther · 2 shared papers, 2023 · strength 0.32
  13. Julia Sidenius Johansen · 2 shared papers, 2023 · strength 0.32
  14. Frank Viborg Mortensen · 2 shared papers, 2020–2022 · strength 0.23
  15. Sture Falkmer · 2 shared papers, 2020–2021 · strength 0.21
  16. Faisal Mahmood · 1 shared paper, 2024 · strength 0.20
  17. Susy Shim · 1 shared paper, 2023 · strength 0.16
  18. Henrik Møller · 1 shared paper, 2022 · strength 0.14
  19. Henriette Engberg · 1 shared paper, 2022 · strength 0.14
  20. Jakob Kirkegård · 1 shared paper, 2022 · strength 0.14
  21. Hans Stødkilde‐Jørgensen · 1 shared paper, 2020 · strength 0.11
  22. Carsten Palnæs Hansen · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.